Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

JOHNSON & JOHNSON JNJ

Healthcare
Johnson & Johnson, through its subsidiaries, is engaged in the research and development, manufacture, and sale of a range of products in the healthcare field. The Company's primary focus is products related to human health and well-being. It operates through two segments: Innovative Medicine and MedTech. The Innovative Medicine segment is focused on various therapeutic areas, including immunology, infectious diseases, neuroscience, oncology, pulmonary hypertension, and cardiovascular and metabolic diseases. Products in this segment are distributed directly to retailers, wholesalers, distributors, hospitals, and healthcare professionals for prescription use. The MedTech segment includes a broad portfolio of products used in the orthopedic, surgery, interventional solutions, cardiovascular intervention, and vision fields. The MedTech segment also offers a commercially available intravascular lithotripsy (IVL) platform for coronary artery disease (CAD) and peripheral artery disease (PAD).


NYSE:JNJ - Post by User

JOHNSON & JOHNSON
<< Previous
 Bullboard Posts
Next >>
User Avatar Image
(0)
•••
Post by mdaneseon Oct 21, 2021 3:10pm
94 Views
Post# 34034116

First Day Hearing in LTL Management Case Conclusion

First Day Hearing in LTL Management Case Conclusion
Yesterday's first day hearing in the chapter 11 case of LTL Management, the newly-created entity spun off from Johnson & Johnson in its Oct. 12 “Texas two-step” divisional merger, concluded with Judge Craig Whitley questioning whether the Western District of North Carolina is the proper venue for the debtor’s case. Read the full analysis here: https://reorg.com/ltl-management-chapter-11/
 
<< Previous
 Bullboard Posts
Next >>
Dealroom for high-potential pre-IPO opportunities